MCID: SKN019
MIFTS: 63

Skin Melanoma

Categories: Cancer diseases, Ear diseases, Skin diseases

Aliases & Classifications for Skin Melanoma

MalaCards integrated aliases for Skin Melanoma:

Name: Skin Melanoma 12 55 15
Cutaneous Melanoma 12 29 6 15 73
Malignant Melanoma of Ear and/or External Auricular Canal 12
Malignant Melanoma of Skin of Trunk Except Scrotum 12
Malignant Melanoma of Skin of Lower Limb 12
Malignant Melanoma of Skin of Upper Limb 12
Melanoma, Cutaneous Malignant 44
Malignant Lower Limb Melanoma 12
Malignant Upper Limb Melanoma 12
Malignant Scalp Melanoma 12
Malignant Trunk Melanoma 12
Malignant Neck Melanoma 12
Malignant Ear Melanoma 12
Malignant Lip Melanoma 12
Melanoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:8923
ICD10 33 C43 C43.9
ICD9CM 35 172 172.9
MeSH 44 C562393
NCIt 50 C3510
SNOMED-CT 68 93655004

Summaries for Skin Melanoma

Disease Ontology : 12 A skin cancer that has material basis in melanocytes.

MalaCards based summary : Skin Melanoma, also known as cutaneous melanoma, is related to melanoma, cutaneous malignant 1 and acral lentiginous melanoma, and has symptoms including pruritus and exanthema. An important gene associated with Skin Melanoma is LINC00937 (Long Intergenic Non-Protein Coding RNA 937), and among its related pathways/superpathways are GPCR Pathway and Cytokine Signaling in Immune system. The drugs Intron A and Keytruda have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and brain, and related phenotypes are homeostasis/metabolism and behavior/neurological

Related Diseases for Skin Melanoma

Diseases related to Skin Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 219)
# Related Disease Score Top Affiliating Genes
1 melanoma, cutaneous malignant 1 33.6 BRAF CDKN2A CDKN2B MITF NRAS TP53
2 acral lentiginous melanoma 32.0 BRAF CDKN2A NRAS
3 melanoma 30.8 BRAF CDKN2A MCAM MIA MITF NRAS
4 mucosal melanoma 30.2 BRAF MITF NRAS
5 spitz nevus 29.8 BRAF CDKN2A TP53
6 squamous cell carcinoma 29.8 BRAF CDKN2A MMP2 NME1 TP53
7 retinoblastoma 29.8 CDKN1A CDKN2A MDM2 TP53
8 malignant spindle cell melanoma 29.7 MITF NRAS PMEL TYR
9 li-fraumeni syndrome 29.6 CDKN1A CDKN2A MDM2 TP53
10 melanoma, uveal 29.4 BRAF CDKN2A MDM2 MITF MMP2 NME1
11 lymphoma, non-hodgkin, familial 29.3 BRAF CASP3 CDKN2B MDM2 NRAS TP53
12 breast cancer 28.3 BRAF CASP3 CDKN1A DRAIC FGF2 MDM2
13 melanoma, cutaneous malignant 6 12.6
14 melanoma, cutaneous malignant 9 12.6
15 melanoma, cutaneous malignant 10 12.6
16 melanoma, cutaneous malignant 5 12.6
17 melanoma, cutaneous malignant 3 12.6
18 melanoma, cutaneous malignant 2 12.6
19 melanoma, cutaneous malignant 8 12.6
20 melanoma, cutaneous malignant 7 12.4
21 melanoma, cutaneous malignant 4 12.4
22 superficial spreading melanoma 11.4
23 skin/hair/eye pigmentation, variation in, 3 11.4
24 tumor predisposition syndrome 11.2
25 amelanotic melanoma 11.1
26 meningeal melanoma 10.3 CDKN2A MITF
27 malignant leptomeningeal tumor 10.3 CDKN2A MITF
28 albinism, ocular, with late-onset sensorineural deafness 10.3 MITF TYR
29 gallbladder melanoma 10.3 MITF PMEL
30 nevus of ota 10.3 BRAF TP53
31 albinism, ocular, with sensorineural deafness 10.3 MITF TYR
32 ring chromosome 7 10.3 MDM2 TP53
33 zika virus infection 10.3 MDM2 TP53
34 halo nevi 10.3 PMEL TYR
35 scrotal carcinoma 10.3 CDKN2A CDKN2B TP53
36 meningeal melanomatosis 10.2 CDKN2A NRAS TP53
37 vitiligo-associated multiple autoimmune disease susceptibility 6 10.2 MITF PMEL TYR
38 bladder squamous cell carcinoma 10.2 CDKN2A TP53
39 hermansky-pudlak syndrome 3 10.2 MITF PMEL TYR
40 leukemia, acute lymphoblastic 3 10.2 CDKN2A CDKN2B TP53
41 vitiligo-associated multiple autoimmune disease susceptibility 1 10.2 MITF PMEL TYR
42 epithelioid cell melanoma 10.2 MCAM MITF TYR
43 tongue disease 10.2 CDKN2A MMP2 TP53
44 small cell sarcoma 10.2 MDM2 NRAS TP53
45 dedifferentiated liposarcoma 10.2 CDKN2A MDM2 TP53
46 liposarcoma 10.2 CDKN2A MDM2 TP53
47 verrucous carcinoma 10.2 CDKN2A MDM2 TP53
48 actinic keratosis 10.2 CDKN2A MMP2 TP53
49 ovarian serous cystadenocarcinoma 10.2 BRAF NRAS TP53
50 cellular schwannoma 10.2 CDKN2A MDM2 TP53

Graphical network of the top 20 diseases related to Skin Melanoma:



Diseases related to Skin Melanoma

Symptoms & Phenotypes for Skin Melanoma

UMLS symptoms related to Skin Melanoma:


pruritus, exanthema

MGI Mouse Phenotypes related to Skin Melanoma:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
2 behavior/neurological MP:0005386 10.41 BRAF CASP3 CDKN1A CDKN2A FGF2 MCAM
3 hematopoietic system MP:0005397 10.41 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
4 cardiovascular system MP:0005385 10.4 BRAF CASP3 CDKN1A CDKN2A FGF2 MCAM
5 cellular MP:0005384 10.4 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
6 integument MP:0010771 10.38 BRAF CASP3 CDKN1A CDKN2A CDKN2B MDM2
7 endocrine/exocrine gland MP:0005379 10.37 BRAF CASP3 CDKN1A CDKN2A CDKN2B MDM2
8 growth/size/body region MP:0005378 10.36 BRAF CASP3 CDKN1A CDKN2A MDM2 MITF
9 immune system MP:0005387 10.36 BRAF CASP3 CDKN1A CDKN2A CDKN2B MCAM
10 mortality/aging MP:0010768 10.34 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
11 craniofacial MP:0005382 10.26 BRAF CASP3 CDKN1A MDM2 MITF MMP2
12 neoplasm MP:0002006 10.23 BRAF CDKN1A CDKN2A CDKN2B FGF2 MDM2
13 digestive/alimentary MP:0005381 10.21 BRAF CASP3 CDKN1A CDKN2A MDM2 MMP9
14 nervous system MP:0003631 10.21 BRAF CASP3 CDKN1A CDKN2A FGF2 MDM2
15 embryo MP:0005380 10.2 BRAF CDKN1A CDKN2A MDM2 MITF NRAS
16 no phenotypic analysis MP:0003012 10.14 CASP3 CDKN1A CDKN2A CDKN2B MCAM MDM2
17 limbs/digits/tail MP:0005371 10.13 BRAF CDKN1A MDM2 MITF MMP9 NRAS
18 muscle MP:0005369 10.13 BRAF CASP3 CDKN1A CDKN2A FGF2 MDM2
19 hearing/vestibular/ear MP:0005377 10.12 BRAF CASP3 CDKN1A FGF2 MITF TP53
20 liver/biliary system MP:0005370 10.05 BRAF CDKN1A CDKN2A MDM2 NME1 NRAS
21 pigmentation MP:0001186 10.02 BRAF CASP3 CDKN2A MDM2 MITF NRAS
22 reproductive system MP:0005389 10 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
23 renal/urinary system MP:0005367 9.92 BRAF CASP3 CDKN1A CDKN2B MDM2 MMP9
24 skeleton MP:0005390 9.77 BRAF CASP3 CDKN1A CDKN2A FGF2 MDM2
25 respiratory system MP:0005388 9.7 BRAF CASP3 CDKN1A CDKN2A MMP2 MMP9
26 vision/eye MP:0005391 9.4 BRAF CASP3 CDKN1A CDKN2A FGF2 MITF

Drugs & Therapeutics for Skin Melanoma

FDA approved drugs:

(show all 9)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
2
Keytruda 18 49 PEMBROLIZUMAB Merck September 2014
3
Mekinist 18 49 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline May of 2013
4
Opdivo 18 49 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014, March 2015
5
Proleukin 18 49 ALDESLEUKIN Chiron January 1998
6
Sylatron 18 49 PEGINTERFERON ALFA-2B Merck April 2011
7
Tafinlar 18 49 DABRAFENIB MESYLATE GlaxoSmithKline May 2013
8
Yervoy 18 49 IPILIMUMAB Bristol-Myers Squibb March 2011
9
Zelboraf 18 49 VEMURAFENIB Roche August of 2011

Drugs for Skin Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 182)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Melphalan Approved Phase 3 148-82-3 4053 460612
3
Peginterferon alfa-2b Approved Phase 3,Phase 2 99210-65-8, 215647-85-1
4
Aldesleukin Approved Phase 3,Phase 2,Phase 1,Not Applicable 85898-30-2, 110942-02-4
5
Trametinib Approved Phase 3,Phase 2,Phase 1 871700-17-3 11707110
6
Nicotinamide Approved, Investigational Phase 3,Phase 2,Phase 1 98-92-0 936
7
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
8
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
9
Nivolumab Approved Phase 3,Phase 2,Phase 1,Not Applicable 946414-94-4
10
Dabrafenib Approved, Investigational Phase 3,Phase 2,Phase 1 1195765-45-7 44462760 44516822
11
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
12
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
13
Pembrolizumab Approved Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 1374853-91-4
14
Vemurafenib Approved Phase 3,Phase 2,Early Phase 1 918504-65-1 23252090 42611257
15
Propranolol Approved, Investigational Phase 2, Phase 3,Phase 1 525-66-6 4946
16
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 59-67-6 938
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
18
Ergocalciferol Approved, Nutraceutical Phase 3,Not Applicable 50-14-6 5280793
19
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3,Not Applicable 1406-16-2
20
Vitamin D3 Approved, Nutraceutical Phase 3,Not Applicable 67-97-0 5280795 6221
21 Molgramostim Investigational Phase 2, Phase 3 99283-10-0
22
BCG vaccine Investigational Phase 2, Phase 3
23 Adjuvants, Immunologic Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1
24 Antiviral Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
25 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1
26 Anti-Infective Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
27 Interferon-alpha Phase 2, Phase 3,Phase 3,Not Applicable
28 interferons Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1
29 Vaccines Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1
30
QS 21 Phase 3 141256-04-4
31 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
32 Antimitotic Agents Phase 3,Phase 2,Phase 1
33 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
34 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
35 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
36 Alkylating Agents Phase 3,Phase 2,Phase 1
37 Liver Extracts Phase 3,Phase 1
38 Freund's Adjuvant Phase 3,Phase 2,Phase 1
39 Anti-HIV Agents Phase 3,Phase 2,Phase 1
40 Anti-Retroviral Agents Phase 3,Phase 2,Phase 1
41 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
42 Interleukin-2 Phase 3,Phase 2,Phase 1,Not Applicable
43 Analgesics Phase 3,Phase 2,Phase 1,Not Applicable
44 Analgesics, Non-Narcotic Phase 3,Phase 2,Phase 1,Not Applicable
45 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
46 Micronutrients Phase 3,Phase 2,Phase 1,Not Applicable
47 Folate Phase 3,Phase 2,Phase 1
48 Nicotinic Acids Phase 3,Phase 2,Phase 1
49 Vitamin B9 Phase 3,Phase 2,Phase 1
50 Trace Elements Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 250)
# Name Status NCT ID Phase Drugs
1 Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients Unknown status NCT01729663 Phase 2, Phase 3 interferon alpha 2b
2 Vaccine Therapy in Treating Patients With Primary Stage II Melanoma Unknown status NCT00005052 Phase 3
3 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
4 PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial) Completed NCT00221702 Phase 3 PegIntron;intron A
5 Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin Completed NCT00003444 Phase 3
6 Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced Melanoma Completed NCT01989572 Phase 3
7 Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma Completed NCT00019682 Phase 3 Montanide ISA 51 VG
8 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma Completed NCT01245062 Phase 3 GSK1120212;Chemotherapy
9 Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed NCT00110019 Phase 3 Carboplatin;Paclitaxel;Sorafenib Tosylate
10 Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome Recruiting NCT01748448 Phase 3 Vitamin D;arachides oleum raffinatum
11 A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma Recruiting NCT03635983 Phase 3
12 Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Recruiting NCT02224781 Phase 3 Dabrafenib;Trametinib
13 PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma Active, not recruiting NCT02288897 Phase 3 PV-10 (10% rose bengal disodium);Dacarbazine, temozolomide or talimogene laherparepvec
14 MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma Active, not recruiting NCT02385214 Phase 3
15 Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma Active, not recruiting NCT01597908 Phase 3 Dabrafenib;Vemurafenib;Trametinib
16 Adjuvant PEG Intron in Ulcerated Melanoma Active, not recruiting NCT01502696 Phase 3
17 A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma Active, not recruiting NCT01584648 Phase 3 dabrafenib;dabrafenib plus trametinib placebo;Trametinib
18 Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Active, not recruiting NCT01763164 Phase 3 MEK162;Dacarbazine
19 A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma Active, not recruiting NCT01667419 Phase 3 Vemurafenib;Placebo
20 Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). Active, not recruiting NCT01682083 Phase 3 Dabrafenib;Trametinib;Placebos
21 Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Active, not recruiting NCT01274338 Phase 3
22 High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Active, not recruiting NCT02506153 Phase 3
23 Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Active, not recruiting NCT01909453 Phase 3 LGX818;MEK162;vemurafenib
24 MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients Not yet recruiting NCT02962947 Phase 2, Phase 3 Propranolol;Placebo
25 Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Suspended NCT02339571 Phase 2, Phase 3
26 SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron) vs. INTRON®A as Adjuvant Therapy for Melanoma (MK-4031-002) Terminated NCT03552549 Phase 2, Phase 3
27 A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma Unknown status NCT00925314 Phase 2
28 Vaccine Therapy in Treating Patients With Stage IV Melanoma Unknown status NCT00126685 Phase 1, Phase 2
29 Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. Unknown status NCT01168050 Phase 2 Nilotinib
30 Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery Unknown status NCT00086866 Phase 2
31 Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma Unknown status NCT02142335 Phase 2 Rituxan
32 Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma Completed NCT01693068 Phase 2 Pimasertib;Dacarbazine
33 Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma Completed NCT03541148 Phase 2
34 Use of 852A in Metastatic Cutaneous Melanoma. Completed NCT00189332 Phase 2 852A
35 Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part) Completed NCT01928940 Phase 2 dabrafenib;trametinib
36 Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma Completed NCT00896480 Phase 2
37 Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery Completed NCT00563823 Phase 2 vatalanib
38 Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma Completed NCT00074230 Phase 1, Phase 2
39 Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma Completed NCT00085306 Phase 2
40 A Study to Assess APO866 for the Treatment of Advanced Melanoma Completed NCT00432107 Phase 2 APO866
41 Taxoprexin Treatment for Advanced Skin Melanoma Completed NCT00249262 Phase 2 Taxoprexin
42 Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma Completed NCT00539591 Phase 2 Peginterferon alfa-2b;Temozolomide;Recombinant interferon alfa-2b
43 A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases Completed NCT02941744 Phase 1, Phase 2 nivolumab;ipilimumab
44 A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread Completed NCT01395121 Phase 2 nilotinib
45 Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma Completed NCT01196416 Phase 1, Phase 2 Cisplatin;Gamma-Secretase Inhibitor RO4929097;Temozolomide;Vinblastine Sulfate
46 Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine Completed NCT00794235 Phase 2 Sorafenib (Nexavar), Dacarbazine (DTIC)
47 Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma Completed NCT00026221 Phase 2
48 MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00866177 Phase 2 Selumetinib
49 Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma Completed NCT00387751 Phase 2 Sorafenib Tosylate
50 A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma Completed NCT02110355 Phase 1, Phase 2 AMG 232;Trametinib;Dabrafenib

Search NIH Clinical Center for Skin Melanoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: melanoma, cutaneous malignant

Genetic Tests for Skin Melanoma

Genetic tests related to Skin Melanoma:

# Genetic test Affiliating Genes
1 Cutaneous Melanoma 29

Anatomical Context for Skin Melanoma

MalaCards organs/tissues related to Skin Melanoma:

41
Skin, Lymph Node, Brain, Liver, Testes, T Cells, Endothelial

Publications for Skin Melanoma

Articles related to Skin Melanoma:

(show top 50) (show all 1437)
# Title Authors Year
1
Cutaneous Melanoma-A Review in Detection, Staging, and Management. ( 30497675 )
2019
2
Overexpression of CDCA8 promotes the malignant progression of cutaneous melanoma and leads to poor prognosis. ( 30431060 )
2019
3
Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness. ( 30447951 )
2019
4
Guidelines of care for the management of primary cutaneous melanoma. ( 30392755 )
2019
5
Targeted Photodynamic-Induced Singlet Oxygen Production by Peptide-Conjugated Biodegradable Nanoparticles for Treatment of Skin Melanoma. ( 29885810 )
2018
6
Pyoderma gangrenosum with its subtype affecting oral mucosa pyostomatitis vegetans following skin melanoma surgical excision in a patient with ulcerative colitis: a case report. ( 29760625 )
2018
7
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations. ( 29794562 )
2018
8
Oral contraceptive use and cutaneous melanoma risk: A french prospective cohort study. ( 29978471 )
2018
9
Potential role of cyclin F mRNA expression in the survival of skin melanoma patients: Comprehensive analysis of the pathways altered due to cyclin F upregulation. ( 29767233 )
2018
10
Macrophages in skin melanoma-the key element in melanomagenesis. ( 29552183 )
2018
11
Central retinal vein occlusion associated with vemurafenib use in metastatic skin melanoma. ( 30173784 )
2018
12
1α, 25-Dihydroxyvitamin D3 alters ectonucleotidase expression and activity in human cutaneous melanoma cells. ( 30548323 )
2018
13
Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers. ( 30548543 )
2018
14
Author Correction: Telomere length and survival in primary cutaneous melanoma patients. ( 30552372 )
2018
15
Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma. ( 30510916 )
2018
16
A study of the clinical characteristics and prognosis of advanced mucosal and cutaneous melanoma in a Chinese population. ( 30511592 )
2018
17
Reflectance confocal microscopy for diagnosing cutaneous melanoma in adults. ( 30521681 )
2018
18
Visual inspection for diagnosing cutaneous melanoma in adults. ( 30521684 )
2018
19
Identification of a robust methylation classifier for cutaneous melanoma diagnosis. ( 30529013 )
2018
20
Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma. ( 30537064 )
2018
21
The COX2 effector microsomal PGE2 synthase-1 is a regulator of immunosuppression in cutaneous melanoma. ( 30538110 )
2018
22
Eruptive cherry angiomas and skin melanoma: a fortuitous association? ( 30543562 )
2018
23
Factors associated with suspected nonmelanoma skin cancers, dysplastic nevus, and cutaneous melanoma among first-time SPOTme screening program participants (2009-2010). ( 30543833 )
2018
24
Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma. ( 30544170 )
2018
25
Delivery of proteins encapsulated in chitosan-tripolyphosphate nanoparticles to human skin melanoma cells. ( 30465996 )
2018
26
A feasibility study of indocyanine green fluorescence mapping for sentinel lymph node detection in cutaneous melanoma. ( 30467004 )
2018
27
Defective levels of both circulating dendritic cells and T-regulatory cells correlate with risk of recurrence in cutaneous melanoma. ( 30470990 )
2018
28
Sirt5 is dispensable for BrafV600E -mediated cutaneous melanoma development and growth in vivo. ( 30471144 )
2018
29
What has changed in the epidemiology of skin melanoma in central Italy during the past 20 years? ( 30480621 )
2018
30
MiR-135b is a novel oncogenic factor in cutaneous melanoma by targeting LATS2. ( 30480622 )
2018
31
Circulating cell-free microRNAs in cutaneous melanoma staging and recurrence or survival prognosis. ( 30481404 )
2018
32
Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnea patients. ( 30487198 )
2018
33
Interplay between small and long non-coding RNAs in cutaneous melanoma: a complex jigsaw puzzle with missing pieces. ( 30499222 )
2018
34
Non-Invasive Analysis of High-Risk Driver Mutations and Gene Expression Profiles in Primary Cutaneous Melanoma. ( 30500343 )
2018
35
Optimal resection margin for head and neck cutaneous melanoma. ( 30408184 )
2018
36
Improving clinical diagnosis of early-stage cutaneous melanoma based on Raman spectroscopy. ( 30410059 )
2018
37
FOXD2-AS1 correlates with the malignant status and regulates cell proliferation, migration, and invasion in cutaneous melanoma. ( 30426532 )
2018
38
Cytoplasmic Pin1 expression is increased in human cutaneous melanoma and predicts poor prognosis. ( 30442923 )
2018
39
Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants. ( 30450100 )
2018
40
Sentinel Lymph Node Biopsy: Past and Present Implications for the Management of Cutaneous Melanoma with Nodal Metastasis. ( 30374897 )
2018
41
Aquaporin-1 Protein Expression of the Primary Tumor May Predict Cerebral Progression of Cutaneous Melanoma. ( 30378011 )
2018
42
Positive margins after surgical excision of locoregional cutaneous melanoma metastasis and their impact on patient outcome. ( 30378546 )
2018
43
Incidence and prognosis of brain metastases in cutaneous melanoma patients: a population-based study. ( 30379726 )
2018
44
Early Diagnosis of Skin Melanoma Metastasis by Means of Dermoscopy and Confocal Microscopy. ( 30383118 )
2018
45
Time Trends in Incidence and Mortality of Cutaneous Melanoma in Germany. ( 30387899 )
2018
46
The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma. ( 30399061 )
2018
47
The long-term prognostic impact of sentinel lymph node biopsy in patients with primary cutaneous melanoma: a prospective study with 10-year follow-up. ( 30402447 )
2018
48
Overexpression of SLC25A15 is involved in the proliferation of cutaneous melanoma and leads to poor prognosis. ( 30403179 )
2018
49
ASO Author Reflections: Hematological Biomarkers of Survival in Cutaneous Melanoma. ( 30324481 )
2018
50
Increased incidence of cutaneous melanoma in organ transplant recipients based on a single-centre longitudinal study in Rome, Italy. ( 30325318 )
2018

Variations for Skin Melanoma

Cosmic variations for Skin Melanoma:

9 (show top 50) (show all 1910)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5611082 TRRAP skin,trunk,malignant melanoma,NS c.100C>T p.P34S 7:98881250-98881250 12
2 COSM1176879 TRRAP skin,trunk,malignant melanoma,NS c.3251C>T p.S1084L 7:98930064-98930064 12
3 COSM328254 TNC skin,trunk,malignant melanoma,NS c.1342C>G p.R448G 9:115086389-115086389 12
4 COSM5610746 TBX22 skin,trunk,malignant melanoma,NS c.1352G>T p.G451V 23:80030900-80030900 12
5 COSM5610663 SMG7 skin,trunk,malignant melanoma,NS c.2811C>T p.F937F 1:183549276-183549276 12
6 COSM5610425 PTPRK skin,trunk,malignant melanoma,NS c.2737G>A p.A913T 6:127996931-127996931 12
7 COSM5610317 PTPRD skin,trunk,malignant melanoma,NS c.2595G>A p.M865I 9:8486222-8486222 12
8 COSM5142 PTEN skin,trunk,malignant melanoma,NS c.112C>T p.P38S 10:87894057-87894057 12
9 COSM231641 PREX2 skin,trunk,malignant melanoma,NS c.1387C>T p.R463C 8:68069080-68069080 12
10 COSM563 NRAS skin,trunk,malignant melanoma,NS c.34G>A p.G12S 1:114716127-114716127 12
11 COSM585 NRAS skin,trunk,malignant melanoma,NS c.183A>T p.Q61H 1:114713907-114713907 12
12 COSM571 NRAS skin,trunk,malignant melanoma,NS c.37G>A p.G13S 1:114716124-114716124 12
13 COSM5049807 NF1 skin,ear,malignant melanoma,NS c.3097C>T p.Q1033* 17:31230366-31230366 12
14 COSM5609545 NF1 skin,trunk,malignant melanoma,NS c.7189+1G>A p.? 17:31343136-31343136 12
15 COSM5049808 NF1 skin,ear,malignant melanoma,NS c.3652C>T p.Q1218* 17:31233157-31233157 12
16 COSM6503455 NF1 skin,trunk,malignant melanoma,NS c.2131C>T p.R711C 17:31226564-31226564 12
17 COSM5609467 MTOR skin,trunk,malignant melanoma,NS c.2638A>G p.T880A 1:11231311-11231311 12
18 COSM5609451 MSH6 skin,trunk,malignant melanoma,NS c.4004A>G p.E1335G 2:47806781-47806781 12
19 COSM232755 MAP2K1 skin,trunk,malignant melanoma,NS c.607G>A p.E203K 15:66481793-66481793 12
20 COSM5609259 KRAS skin,trunk,malignant melanoma,NS c.130G>A p.V44I 12:25227394-25227394 12
21 COSM5609255 KIT skin,trunk,malignant melanoma,NS c.575G>A p.G192D 4:54698521-54698521 12
22 COSM5609145 IL36A skin,trunk,malignant melanoma,NS c.359C>T p.S120F 2:113007926-113007926 12
23 COSM110485 GRIN2A skin,ear,malignant melanoma,NS c.3217G>A p.E1073K 16:9764327-9764327 12
24 COSM5609011 GRIN2A skin,trunk,malignant melanoma,NS c.2252G>A p.G751E 16:9798381-9798381 12
25 COSM109660 GRIN2A skin,ear,malignant melanoma,NS c.4097C>T p.P1366L 16:9763447-9763447 12
26 COSM5608954 GNAQ skin,trunk,malignant melanoma,NS c.264G>T p.Q88H 9:77922218-77922218 12
27 COSM1205523 EPHB4 skin,trunk,malignant melanoma,NS c.2177C>T p.S726L 7:100807522-100807522 12
28 COSM5608400 EPHA3 skin,trunk,malignant melanoma,NS c.2525G>A p.R842Q 3:89450205-89450205 12
29 COSM141892 CNR1 skin,ear,malignant melanoma,NS c.145C>T p.P49S 6:88145130-88145130 12
30 COSM141856 CHRM3 skin,ear,malignant melanoma,NS c.1741T>A p.F581I 1:239909192-239909192 12
31 COSM13830 CDKN2A skin,trunk,malignant melanoma,NS c.341C>A p.P114H 9:21971018-21971018 12
32 COSM13281 CDKN2A skin,trunk,malignant melanoma,NS c.205G>T p.E69* 9:21971154-21971154 12
33 COSM12503 CDKN2A skin,trunk,malignant melanoma,NS c.334C>G p.R112G 9:21971025-21971025 12
34 COSM476 BRAF skin,trunk,malignant melanoma,NS c.1799T>A p.V600E 7:140753336-140753336 12
35 COSM471 BRAF skin,ear,malignant melanoma,NS c.1790T>G p.L597R 7:140753345-140753345 12
36 COSM27639 BRAF skin,ear,malignant melanoma,NS c.1780G>A p.D594N 7:140753355-140753355 12
37 COSM1448615 BRAF skin,trunk,malignant melanoma,NS c.1390G>A p.G464R 7:140781618-140781618 12
38 COSM1125 BRAF skin,ear,malignant melanoma,NS c.1790T>A p.L597Q 7:140753345-140753345 12
39 COSM478 BRAF skin,ear,malignant melanoma,NS c.1801A>G p.K601E 7:140753334-140753334 12
40 COSM5608955 skin,trunk,malignant melanoma,NS c.177G>T p.Q59H 9:77922218-77922218 12
41 COSM1645467 skin,trunk,malignant melanoma,NS c.856G>A p.E286K 17:7673764-7673764 12
42 COSM99924 skin,trunk,malignant melanoma,NS c.856G>A p.E286K 17:7673764-7673764 12
43 COSM5610316 skin,trunk,malignant melanoma,NS c.2595G>A p.M865I 9:8486222-8486222 12
44 COSM5610424 skin,trunk,malignant melanoma,NS c.2737G>A p.A913T 6:127996931-127996931 12
45 COSM1176880 skin,trunk,malignant melanoma,NS c.3251C>T p.S1084L 7:98930064-98930064 12
46 COSM231642 skin,trunk,malignant melanoma,NS c.1387C>T p.R463C 8:68069080-68069080 12
47 COSM5610426 skin,trunk,malignant melanoma,NS c.2773G>A p.A925T 6:127996931-127996931 12
48 COSM5609258 skin,trunk,malignant melanoma,NS c.130G>A p.V44I 12:25227394-25227394 12
49 COSM5611083 skin,trunk,malignant melanoma,NS c.100C>T p.P34S 7:98881250-98881250 12
50 COSM5609544 skin,trunk,malignant melanoma,NS c.7189+1G>A p.? 17:31343136-31343136 12

Expression for Skin Melanoma

Search GEO for disease gene expression data for Skin Melanoma.

Pathways for Skin Melanoma

Pathways related to Skin Melanoma according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.75 BRAF CDKN1A CDKN2A CDKN2B FGF2 MDM2
2
Show member pathways
13.38 BRAF CASP3 CDKN1A FGF2 MMP2 MMP9
3
Show member pathways
13.09 CASP3 CDKN1A CDKN2A FGF2 MDM2 MMP9
4
Show member pathways
13.03 CASP3 CDKN1A FGF2 MDM2 NRAS TP53
5
Show member pathways
12.89 BRAF CASP3 CDKN1A CDKN2A MDM2 MMP9
6
Show member pathways
12.84 CASP3 CDKN1A CDKN2A MDM2 NRAS TP53
7
Show member pathways
12.81 BRAF CDKN1A CDKN2A CDKN2B FGF2 NRAS
8 12.79 BRAF CASP3 FGF2 NRAS TP53
9
Show member pathways
12.76 CDKN1A FGF2 MDM2 NRAS TP53
10
Show member pathways
12.62 CDKN1A FGF2 MMP2 NRAS TP53
11
Show member pathways
12.6 CDKN1A CDKN2A CDKN2B MDM2 TP53
12
Show member pathways
12.57 BRAF CASP3 MDM2 MMP2 MMP9 NRAS
13
Show member pathways
12.57 BRAF CDKN1A CDKN2A CDKN2B FGF2 MDM2
14
Show member pathways
12.51 BRAF CDKN1A MDM2 NRAS TP53
15 12.48 CASP3 CDKN1A CDKN2A MDM2 MMP9 NRAS
16
Show member pathways
12.47 CASP3 MDM2 NRAS TP53
17 12.47 CDKN1A CDKN2A CDKN2B NRAS TP53
18 12.45 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
19
Show member pathways
12.43 CASP3 CDKN1A CDKN2A MDM2 TP53
20 12.41 CDKN1A CDKN2A CDKN2B MDM2 TP53
21
Show member pathways
12.38 CDKN1A CDKN2A CDKN2B TP53
22
Show member pathways
12.38 BRAF CDKN1A CDKN2A CDKN2B MITF NRAS
23 12.32 CASP3 CDKN1A MDM2 TP53
24 12.31 CDKN1A MDM2 MITF MMP9 TP53
25
Show member pathways
12.3 BRAF CASP3 MITF NRAS TP53
26
Show member pathways
12.28 CASP3 CDKN1A MDM2 TP53
27
Show member pathways
12.25 BRAF CASP3 CDKN1A MDM2 NRAS TP53
28 12.21 BRAF CASP3 CDKN1A FGF2 MDM2 MMP2
29 12.19 BRAF CASP3 MDM2 TP53
30 12.19 CASP3 CDKN1A MDM2 NRAS TP53
31 12.19 BRAF CASP3 CDKN1A MMP2 MMP9 TP53
32
Show member pathways
12.18 BRAF CASP3 NRAS TP53
33 12.17 CASP3 CDKN1A CDKN2A CDKN2B MDM2 NRAS
34 12.16 CDKN1A CDKN2A CDKN2B MDM2 NRAS TP53
35
Show member pathways
12.15 BRAF CDKN1A CDKN2B MDM2 NRAS
36 12.11 CDKN1A CDKN2A MDM2 MMP2 TP53
37 12.1 CDKN1A MDM2 MMP2 TP53
38 12.09 BRAF CDKN1A NRAS TP53
39 12.04 CDKN1A CDKN2A MDM2 NRAS TP53
40 12.03 CDKN1A FGF2 MMP2 MMP9 TP53
41 11.99 BRAF CDKN1A CDKN2A MDM2 TP53
42 11.92 CASP3 MMP2 NRAS
43 11.92 CASP3 CDKN1A CDKN2B TP53
44 11.89 BRAF CDKN1A CDKN2A MDM2 NRAS TP53
45 11.87 FGF2 MMP2 MMP9
46 11.87 CDKN1A MDM2 TP53
47
Show member pathways
11.86 CDKN1A MDM2 TP53
48 11.83 CDKN1A MDM2 TP53
49
Show member pathways
11.83 BRAF CASP3 NRAS
50 11.82 MMP9 NME1 TP53

GO Terms for Skin Melanoma

Biological processes related to Skin Melanoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.96 CDKN1A CDKN2A CDKN2B NME1 TP53
2 positive regulation of gene expression GO:0010628 9.95 BRAF CDKN2A MDM2 MITF TP53
3 negative regulation of apoptotic process GO:0043066 9.87 BRAF CASP3 CDKN1A MDM2 MITF MMP9
4 cell cycle arrest GO:0007050 9.78 CDKN1A CDKN2A CDKN2B TP53
5 cellular response to drug GO:0035690 9.74 BRAF NME1 TP53
6 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.7 CDKN1A MDM2 TP53
7 response to cAMP GO:0051591 9.69 BRAF NME1 TYR
8 cytokine-mediated signaling pathway GO:0019221 9.63 CASP3 CDKN1A FGF2 MMP2 MMP9 TP53
9 response to antibiotic GO:0046677 9.61 CASP3 MDM2 TP53
10 melanin biosynthetic process GO:0042438 9.59 PMEL TYR
11 negative regulation of fibroblast migration GO:0010764 9.58 BRAF FGF2
12 amyloid fibril formation GO:1990000 9.58 CDKN2A MDM2
13 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.58 CASP3 CDKN1A CDKN2A
14 obsolete negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 9.54 CDKN2A CDKN2B
15 negative regulation of phosphorylation GO:0042326 9.54 CDKN1A CDKN2A CDKN2B
16 signal transduction by p53 class mediator GO:0072331 9.49 CDKN1A TP53
17 cellular response to actinomycin D GO:0072717 9.46 MDM2 TP53
18 replicative senescence GO:0090399 9.43 CDKN1A CDKN2A TP53
19 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.26 FGF2 MDM2 MMP2 MMP9
20 Ras protein signal transduction GO:0007265 9.02 CDKN1A CDKN2A FGF2 NRAS TP53

Molecular functions related to Skin Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 9.13 CDKN2A MDM2 TP53
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.92 CASP3 CDKN1A CDKN2A CDKN2B

Sources for Skin Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....